TechSeeker Profile

Altamira Therapeutics Ltd (AKA: Auris Medical)
Profile last edited on: 2/28/2023

NO Business Identifier is currently available for this company.
TS Type
Small Corp
Status
Active
Year Founded
2003
Last Involved Year
2021

Key People / Management

  Thomas Meyer -- Founder, Chairman, CEO & MD

  Marcel Gremaud -- Chief Financial Officer

  Covadonga Paneda -- Chief Operating Officer

  Samuel A Wickline -- Chief Scientific Adviser

Location Information

2 Church Street
Hamilton, HM 11
   (441) 295-5950
   www.altamiratherapeutics.com

Public Profile

Auris Medical is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of oligonucleotides for extrahepatic therapeutic targets (OligoPhoreTM platform; preclinical), nasal sprays for protection against airborne viruses and allergens (BentrioTM; pre-commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
Bermuda
Employment
14
Revenue
$0.6M
Public/Private
Publicly Traded
Stock Info
NASDAQ : CYTO
Received SBIR $$
No

Techseeker firm in the news

There are no news available.